bioAffinity Technologies (NASDAQ:BIAF) is rolling out CyPath Lung, an accurate, non-invasive and cost-effective test for the early detection of lung cancer, in the U.S. Southwest before a staged nationwide launch.
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
Hepion to highlight AI-POWR platform at AI webinar
Hepion Pharmaceuticals (NASDAQ:HEPA) will highlight its AI-POWR platform in a presentation during a webinar on March 23 entitled, “How Artificial Intelligence is Changing Drug Discovery.” The webinar is being co-hosted...
Dawson James starts NRx Pharma at buy; PT $3.00
Dawson James Securities initiated coverage of NRx Pharmaceuticals (NASDAQ:NRXP) with a “buy” rating and $3.00 price target. The stock closed at 68 cents on March 16. NRx Pharmaceuticals is a clinical-stage...
Stifel starts Theseus Pharma at buy; PT $24
Stifel initiated coverage of Theseus Pharmaceuticals (NASDAQ:THRX) with a “buy” rating and $24 price target. The stock closed at $7.35 on March 15. Theseus is a clinical-stage, small molecule oncology company that...
HCW ups Aravive PT on higher probability of success for batiraxcept
H.C. Wainwright raised its price target for Aravive (NASDAQ:ARAV) to $12 from $7 after increasing its probability of success for batiraxcept to 55% from 35% for platinum-resistant ovarian cancer (PROC) “to further value...
RJ highlights takeaways from KOL presentations on Profound’s TULSA-PRO
In a new report, Raymond James analyst, Rahul Sarugaser, Ph.D., outlined his five main takeaways from presentations from four key opinion leaders – Yale, UCLA, Mayo Clinic and WellSpan Health – about their clinical...
OpSens in specialty diagnostics pact with Premier for SavvyWire
OpSens (TSX:OPS; OTCQX:OPSSF) was awarded a national group purchasing agreement for interventional specialty diagnostics with Premier, a leading healthcare improvement company uniting an alliance with approximately...
Reneo reaches target enrollment in pivotal trial in primary mitochondrial myopathies
Reneo Pharmaceuticals (NASDAQ:RPHM) achieved its target enrollment of 200 patients in the pivotal STRIDE study of mavodelpar in primary mitochondrial myopathies (PMM). Topline data from the STRIDE study are expected in...
Dylan Dupuis joins ROTH MKM healthcare research team
Dylan Dupuis, Ph.D., has joined ROTH MKM’s healthcare research team as managing director, senior research analyst covering biotechnology. His research coverage is expected to include micro-cap and small-cap...
BTIG starts CymaBay at buy; PT $15
BTIG launched coverage of CymaBay Therapeutics (NASDAQ:CBAY) with a “buy” rating and $15 price target. The stock closed at $9.11 on March 8. Analyst Julian Harrison writes that the company’s seladelpar is well...
WB starts Mesoblast at OP; fair value estimate $8
William Blair initiated coverage of Mesoblast (NASDAQ:MESO) with an “outperform” rating and fair value estimate of $8. The stock closed at $3.03 on March 8. Mesoblast is developing mesenchymal lineage cell-derived...
BTIG starts Moonlake at buy; PT $36
BTIG initiated coverage of Moonlake Immunotherapeutics (NASDAQ:MLTX) with a “buy” rating and $36 price target. The stock closed at $23.70 on March 8. “We see Moonlake’s sonelokimab (SLK) well-positioned to emerge as the...
Echelon starts Valeo Pharma at speculative buy; PT $1 (Canadian)
Echelon Capital Markets initiated coverage of Valeo Pharma (TSX:VPH) with a “speculative buy” rating and price target of $1 (Canadian). The stock closed at 55 cents on March 8. Valeo commercializes de-risked, innovative...
Just a few of the companies we’ve highlighted along the way
